PAP
RVPH

Persistent Asset Partners’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Persistent Asset Partners’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-57
Closed -$228 – 453
2025
Q4 		$228 Buy
+57
New +$634 ﹤0.01% 349

Other funds holding RVPH

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Persistent Asset Partners's RVPH Position: Q4 2025 in Review

Persistent Asset Partners sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q4 2025, closing a stake of 29,695 shares — an estimated $330K sold.

Persistent Asset Partners first reported a position in RVPH in Q4 2024 and held it in 4 quarters. The position peaked at $305K in Q4 2024. 48 funds tracked by Wall St. Rank hold RVPH as of Q4 2025.

  • Persistent Asset Partners reported no remaining REVIVA PHARMA HLDGS INC position as of Q4 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 29,695 REVIVA PHARMA HLDGS INC shares in Q4 2025, an estimated $330K.
  • Persistent Asset Partners first reported a position in REVIVA PHARMA HLDGS INC in Q4 2024 and held it in 4 quarters.
  • Persistent Asset Partners's REVIVA PHARMA HLDGS INC position peaked at $305K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q4 2025.

Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.